Eli Lilly Alzheimer’s Drug Gains FDA Breakthrough Designation By Bloomberg
(Bloomberg) -- Eli Lilly & Co (NYSE:LLY) rose after its experimental drug for Alzheimer’s disease gained breakthrough status from U.S. regulators, a designation that will speed its consideration for approval. Biogen's (NASDAQ:BIIB) Aduhelm was approved for Alzheimer’s on June 7 after gaining breakthrough status in a controversial move by the Food and Drug Administration. Lecanemab, another drug being developed by Biogen and its partner Eisai (OTC:ESALY), received the same designation Wednesday. Lilly gained as much as 8.7% in trading before U.S. markets opened. Biogen fell 3.5%. Like Aduhelm, Lilly’s donanemab attacks amyloid, an abnormal protein...
Continue reading